Deal Roundup: Novartis Options Sironax’s Neuro Platform, Plus Moves from Revolution, Iambic, Sernova, and Eledon

Novartis; Sironax; Brain Delivery Module; neuroscience; blood-brain barrier; biotech; dealmaking; Revolution Medicines; Iambic; Sernova; Eledon

ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals

ALTO-203; Alto Neuroscience; Phase 2 trial; major depressive disorder; EEG biomarkers; theta/beta ratio; attention; wakefulness; William Blair; drug activity; future development

Genentech’s Kristin Bittenbender Named BIO Board Chair Amid Industry Challenges

BIO; Genentech; Kristin Bittenbender; board chair; biotech industry; FDA; existential threats; leadership change; biotechnology policy

Ousted ACIP Members Criticize RFK Jr.’s ‘Destabilizing’ Changes to U.S. Vaccine Policy

ACIP; RFK Jr.; vaccine policy; CDC; committee dismissal; public health; vaccine recommendations; destabilizing decisions

FDA Launches New Priority Review Voucher Program Aligned with National Priorities

FDA; priority review voucher; CNPV; biopharma; drug approval; national priorities; accelerated review; unmet public health needs